Survey of cutaneous adverse reactions to targeted cancer therapies: value of dermatological advice.

Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Società Italiana Di Dermatologia E Sifilografia
Giovanni DamianiOncoSkin working group

Abstract

Target-therapy offers a better efficacy for several cancers, with less toxic adverse effects, if compared with traditional chemotherapy. However cutaneous complications are increased in number and complexity. The severity of these reactions positively correlates with efficacy, and the management of these reactions is challenging. This was a multicenter cross-sectional study on a consecutive series of adult patients with incident cutaneous reactions linked to targeted cancer therapies observed in five referral centers for cancer treatment in the province of Bergamo and Brescia in northern Italy. Each center was asked to collect data on the first 5 consecutive cases of severe adverse cutaneous events observed during a one-week surveillance period. From June to October 2012, 25 patients with cutaneous adverse reactions linked to targeted therapies were included in the study. The main prescribed drugs were cetuximab (52%) and erlotinib (20%) and the most common reactions were folliculitis/pustules (40%) and rash/erythema (40%). Hand-foot reaction syndrome was present in 8% of patients. A total of 30% of patients treated for a cutaneous reaction underwent a consultation by a dermatologist. In these patients the rate of oncologic the...Continue Reading

References

Jul 23, 2008·Archives of Dermatology·Rebecca G PomerantzLarisa J Geskin
May 11, 2012·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Lisa ZimmerDirk Schadendorf
Jan 15, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Roberta GrandeTeresa Gamucci
Oct 2, 2013·Clinics in Dermatology·Bianca Maria Piraccini, Aurora Alessandrini
Jan 8, 2015·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Alexandre ChanMario E Lacouture
Jan 27, 2016·World Journal of Gastroenterology : WJG·Akiko KuboYasuhide Yamada
Jun 17, 2016·Molecular & Cellular Oncology·Martin Holcmann, Maria Sibilia
Nov 12, 2016·Frontiers in Oncology·Ajit Venniyoor, Bassim Al Bahrani
Oct 27, 2017·Stem Cells Translational Medicine·Federica PapaccioVirginia Tirino
Dec 23, 2017·Frontiers in Cell and Developmental Biology·Valentina Comunanza, Federico Bussolino
Feb 3, 2018·Experimental Cell Research·Domenico Ribatti
Feb 9, 2018·Pharmacology & Therapeutics·Stephanie Annett, Tracy Robson

❮ Previous
Next ❯

Citations

May 3, 2019·Journal of Patient-reported Outcomes·Kaori YagasakiHiroko Komatsu
Jan 29, 2021·Dermatology : International Journal for Clinical and Investigative Dermatology·Paolo GisondiGiampiero Girolomoni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Related Papers

Ugeskrift for laeger
Sumangali Chandra PrasadAnette Bygum
Indian Journal of Dermatology, Venereology and Leprology
Rachel A PaveyRamesh M Bhat
Indian Journal of Dermatology, Venereology and Leprology
J S Pasricha
The New England Journal of Medicine
Wilfried BudachBernhard Homey
Clinical and Experimental Rheumatology
Stefania CartellaPaolo Airo
© 2022 Meta ULC. All rights reserved